Activity
11K followers
-
Daisy Wolf shared thisAI is making healthcare advice cheap and ubiquitous. But once you know what you need, there’s still no good way to actually get it. And knowing what it will cost you? Seemingly impossible! Healthcare should be shoppable. The AI doctor is here. Nobody’s built the store. That’s why we Andreessen Horowitz are proud to lead the $120M Series B of General Medicine, the first true healthcare store. Building this takes insanely detailed knowledge of the infrastructure and weeds of healthcare, pharmacy, and insurance. There are no people better equipped than TJ Parker, Elliot Cohen, and Ashwin Muralidharan, the team behind PillPack (one of the largest exits in the space!) and Amazon Health & Pharmacy. cc Vineeta Agarwala, Jorge Conde, Eva Steinman, BoxGroup, Eli Lilly and Company, MatrixDaisy Wolf shared thisGeneral Medicine has raised $120M in Series B financing led by Andreessen Horowitz. We’re building the healthcare store: a place where customers can search, compare, and buy care, see prices before deciding, and get guidance from a licensed clinician. Today, the store includes more than 2,900 products and services across medications, labs, telehealth, specialist e-consults, and select in-person visits and procedures. This funding will help us expand the store into more categories of care for customers nationwide. Read more from TJ Parker: https://lnkd.in/g3wVSnsy
-
Daisy Wolf shared thisWe at Andreessen Horowitz are proud to lead a $7.5M round into Aleph, which is building an autonomous surgical robot. These robot surgeons will eventually be able to learn & perform any procedure, making critical care accessible to all. Dylan McGuire and Ryan McGuire are visionaries and we're honored to partner with them on this journey, alongside BoxGroup, Reveille VC, Forward Deployed Venture Capital, Valkyrie, Discipulus Ventures, maniac ventures, and Constellation. cc Eva Steinman Oliver Hsu
-
Daisy Wolf reposted thisDaisy Wolf reposted this"Who is making sure that AI answers in a doctor's clinical AI tool is safe and correct?" Frontier models care - but ChatGPT or Claude shouldn't grade itself when it's deployed in a health system Specialized healthcare AI model builders care - but they have the same grading concern Healthcare system and providers care - but they're actively looking for the source of truth for whether models are safe for their context and environment Academics care - and continue to debate health AI effectiveness while looking for representative real-world data The US government is starting to care - HHS just appointed a deputy commissioner for technology and artificial intelligence So everyone cares. But there hasn't been an incentives-aligned, expert healthcare organization that exists to help ensure AI alignment that is also able to help improve the models at their training source. This is something Engy Ziedan and Protege's DataLab researchers think about daily. With Protege's healthcare data, expertise, and scale, we're actively working with model builders to help solve this pressing issue. Explanation and interview with Engy, Daisy Wolf, Eva Steinman on the a16z Bio + Health Raising Health podcast linked below!
-
Daisy Wolf shared thisI've had the privilege of working with Mehul Mehta for the last five years – first as a colleague at a16z where I learned so much from him, and now as a very proud investor in Ferry Health. Mehul, Keyur Mehta, and Andrew Buie are special humans building something that makes healthcare work the way it should, starting with the simple, maddening problem of actually getting a doctor's appointment.Daisy Wolf shared thisIn May of 2023, Keyur Mehta and I got a call from Mom saying Dad was in the hospital. We both rushed home to Austin. Three days later, Dad was discharged and we were relieved to be back home, armed with a long list of follow-up care to organize. We logged in to Dad’s insurance portal, pulled up the “Find a Doctor” directory, and compiled a spreadsheet of every neurologist, cardiologist, and physical therapist in Austin. We started calling providers’ offices and encountered a tangled mess. Incorrect phone numbers, retired providers, and even a practice with a >1-year waitlist. Our difficulty navigating the healthcare system for Dad is unfortunately not unique. In fact, every single person we’ve talked to on this journey - patients, team members, customers - has experienced their own version of it. We started Ferry Health to make navigating healthcare as easy as possible. Ferry’s AI-powered assistant goes beyond reminders or suggesting options for a patient to call. Ferry actually does the work for the patient - connecting patients with any provider, not just those with online scheduling. Ferry turns requests like “find me a neurologist near 78734 that can see a patient for persistent unsteadiness and vertigo” into a booked appointment in just a few messages back and forth, exactly the assistant we needed when helping Dad three years ago. Through our partnerships with health plans, health systems, and digital health companies, more than 1 million patients have access to Ferry today. It has been a dream come true to build Ferry over the last couple years. A dream to co-found this business with my brother Keyur and one of my best friends, Andrew Buie. A dream to work with our incredibly talented team of 30. And, most of all, a dream to hear the feedback we get from patients every single day. As a patient recently told us, “Well, since I didn't have to do anything to get scheduled, it was great. 5/5.” Today, we are excited to share that we’ve raised $9M in funding from my former colleagues at Andreessen Horowitz as well as Index Ventures, Avid Ventures, Layout Ventures, and more. Thank you to Anastassia Gliadkovskaya for telling our story - a link to her coverage in the comments below!
-
Daisy Wolf reposted thisDaisy Wolf reposted thisThe data curation requests we get from frontier labs have changed shape. Our co-founder and Chief Scientific Officer Engy Ziedan joined Andreessen Horowitz's Daisy Wolf and Eva Steinman on a16z Bio + Health's Raising Health Podcast to talk about what that shift looks like from where we sit. Early on, as Engy puts it, the asks were consumer-shaped. Can the model hold an intelligent conversation? Is it aligned? Is it safe? Is it reasonably sound when someone asks it a medical question? Very large foundation models became our early customers - the consumer was the market they wanted to win first. Then those same labs started to see how much revenue was sitting in enterprise settings. So now, requests we field today land somewhere between consumer needs and enterprise needs. Doing both is difficult. Our belief: you only get both from real-world data — the kind generated by people doing their actual work, in their actual context. Can't get this synthetically. More from Engy in the clip, and full episode in the comments!
-
Daisy Wolf reposted thisDaisy Wolf reposted thisThe data curation requests we get from frontier labs have changed shape. Our co-founder and Chief Scientific Officer Engy Ziedan joined Andreessen Horowitz's Daisy Wolf and Eva Steinman on a16z Bio + Health's Raising Health Podcast to talk about what that shift looks like from where we sit. Early on, as Engy puts it, the asks were consumer-shaped. Can the model hold an intelligent conversation? Is it aligned? Is it safe? Is it reasonably sound when someone asks it a medical question? Very large foundation models became our early customers - the consumer was the market they wanted to win first. Then those same labs started to see how much revenue was sitting in enterprise settings. So now, requests we field today land somewhere between consumer needs and enterprise needs. Doing both is difficult. Our belief: you only get both from real-world data — the kind generated by people doing their actual work, in their actual context. Can't get this synthetically. More from Engy in the clip, and full episode in the comments!
-
Daisy Wolf reposted thisDaisy Wolf reposted thisPeople often ask why we named the company Pomelo. Our name comes from a simple idea: the thick, protective rind of a pomelo fruit. That idea became the foundation for our company—creating a continuous, protective layer of care around families. We started by confronting the maternal health crisis in the United States. Five years later, Pomelo Care supports nearly 7% of U.S. births and covers over 25 million lives, with 40+ peer-reviewed studies proving that proactive care reduces preterm births, NICU stays, emergency room visits, and healthcare spending. Our virtual medical practice has expanded beyond pregnancy and postpartum to care for women and children across every stage of life. With that growth, we knew we needed a visual identity that reflected who we are today and where we’re headed next. Today, I am proud to introduce the new Pomelo. Designed alongside Pentagram, our new look brings proactive care to life through connected letterforms where the "m" proactively reaches out to support the "e"—symbolizing our commitment to connected, continuous care. An adaptive Pom symbol, inspired by the fruit's protective rind, flexes with changing health needs, while warm, fruit-inspired colors balance humanity with our clinical rigor. Building this company has always been deeply personal to me. I started Pomelo because healthcare shouldn't wait for something to go wrong before it shows up for you. Over the past five years, watching our care team show up for families at 2 a.m., catch complications early, and stay step-for-step with patients through every high and low is the true heartbeat of Pomelo. Our look has evolved, but my promise remains identical to day one: we will never stop working to raise the standard of healthcare for every woman and child. To our team and the team at Pentagram—thank you for bringing this vision to life. Welcome to the new Pomelo. Read my blog post to learn more about the story behind our new brand: https://lnkd.in/gQP7Xze5
-
Daisy Wolf shared thisCheck it out ⬇️Daisy Wolf shared thisAI in healthcare is here. More than 300 million people use ChatGPT for healthcare questions every week. Protege DataLab analysis shows that nearly a third of all SOAP notes are now written by AI. Right now, AI is now extraordinarily good at tasks where you can train it on “the right answer.” But what if there isn’t one “right” answer? Are the AI models of today actually good doctors… or are they just good at the test? This is the challenge in healthcare AI today: the verification ceiling. Benchmarks have hit the issue medicine has noticed decades ago: trials measure efficacy, but the real world cares about effectiveness. Today, benchmarks lack even a good measure of efficacy and are far away from effectiveness. Training data and compute may not be the only binding constraints. Instead, we are constrained by learning how to know when the model was right. Protege’s DataLab dug into the data with the team at Andreessen Horowitz to understand how to build healthcare AI benchmarks that reliably produce models that produce real health gains, not just good test scores. Read the full analysis here: https://lnkd.in/gYJAamZ8 Engy Ziedan Protege Allison Fox Matt Turk Zoe Li Alex Muir Caleb Lee
-
Daisy Wolf reposted thisThrilled to celebrate several team milestones: one year anniversary for Evan and Neeknaz, the promotions of Matthew and Debbie, and welcoming new team members Charlize, Yi, and Ally. We're STILL growing and hiring for multiple roles across operations and engineering. Join us and bring the best of consumer tech to Medicaid - the nation's largest healthcare program. • Senior Operations Associate (2+ years in consulting, banking, startups): https://lnkd.in/ggQmfFtm • Product Operations Associate (New grad): https://lnkd.in/gQrNTGDk • Senior Software Engineer: https://lnkd.in/gmVkJFGr https://lnkd.in/gYtqUScgDaisy Wolf reposted this📸 Our wall of Polaroids got a little more crowded this month, which is always a good sign. Congratulations to Matthew Co and Debbie Adewale on their promotions, to Evan Fisher and Neeknaz Abari on one year at Fortuna, and a warm welcome to Charlize Trostinsky, Yi Qian, and Ally Steinman!
-
Daisy Wolf reacted on thisDaisy Wolf reacted on thisGeneral Medicine has raised a $120M Series B led by Andreessen Horowitz. We're using it to build the healthcare store. Healthcare makes you navigate a complicated system before you can even get care: which specialty, what kind of visit, whether you need a referral, how much it might cost. It gives power to everyone except the person who actually needs care.Thats backwards. People need to be able to see prices, compare options, and talk to experts.Healthcare needs a store, and General Medicine is building it. https://lnkd.in/gNx9r-7J
-
Daisy Wolf reacted on thisDaisy Wolf reacted on thisWe're thrilled to lead General Medicine’s $120M Series B as they build the general store for healthcare. General Medicine is built on the belief that facilitating access to care is a core part of delivering it. The company brings patient history, ongoing clinical guidance, transparent pricing, and help accessing care into one experience. Its own medical group combined with a marketplace of external clinicians connects patients almost immediately with services far beyond what a single practice could ever provide. Alongside its direct consumer offering, General Medicine is also building for the enterprise. The same underlying infrastructure for clinical guidance, transparent pricing, and rapid access that General Medicine has already built can be ‘turned on’ for consumers in partnership with any number of enterprise organizations. We’re excited that the PillPack team is back together. Congrats, TJ Parker, Elliot Cohen, Ashwin Muralidharan, and the General Medicine team! By Vineeta Agarwala, Jorge Conde, Daisy Wolf, and Eva Steinman
-
Daisy Wolf reacted on thisDoctors, both human and AI, help guide our care. But once you know what you need, what do you buy? Where do you buy it? How much are you going to pay? Healthcare needs a store. Andreessen Horowitz is thrilled to lead General Medicine’s Series B round to support TJ Parker, Elliot Cohen and Ashwin Muralidharan on this mission. cc: Vineeta Agarwala, Daisy Wolf, Eva SteinmanDaisy Wolf reacted on thisWe're thrilled to lead General Medicine’s $120M Series B as they build the general store for healthcare. General Medicine is built on the belief that facilitating access to care is a core part of delivering it. The company brings patient history, ongoing clinical guidance, transparent pricing, and help accessing care into one experience. Its own medical group combined with a marketplace of external clinicians connects patients almost immediately with services far beyond what a single practice could ever provide. Alongside its direct consumer offering, General Medicine is also building for the enterprise. The same underlying infrastructure for clinical guidance, transparent pricing, and rapid access that General Medicine has already built can be ‘turned on’ for consumers in partnership with any number of enterprise organizations. We’re excited that the PillPack team is back together. Congrats, TJ Parker, Elliot Cohen, Ashwin Muralidharan, and the General Medicine team! By Vineeta Agarwala, Jorge Conde, Daisy Wolf, and Eva Steinman
-
Daisy Wolf reacted on thisDaisy Wolf reacted on thisGeneral Medicine has raised $120M in Series B financing led by Andreessen Horowitz. We’re building the healthcare store: a place where customers can search, compare, and buy care, see prices before deciding, and get guidance from a licensed clinician. Today, the store includes more than 2,900 products and services across medications, labs, telehealth, specialist e-consults, and select in-person visits and procedures. This funding will help us expand the store into more categories of care for customers nationwide. Read more from TJ Parker: https://lnkd.in/g3wVSnsy
-
Daisy Wolf reacted on thisI’m stepping back from venture capital for the best possible reason – to get back to operating. Starting today, I’m CEO of General Medicine, leading the company alongside my friends and cofounders Ashwin Muralidharan and Elliot Cohen. Ashwin explains it below, and I’ll just add that these are my two favorite people to work with, and we have lots to do. More soon.Daisy Wolf reacted on thisI joined Amazon Pharmacy in 2019 to lead pricing because I wanted my work to really matter. I didn’t know much about pharmacy pricing, or healthcare, for that matter. But, I knew how to build marketplaces and create simple, lovable consumer experiences, even when everything under the hood was wildly complex. I also thought the newly acquired PillPack team was exceptional and that we might have some fun along the way. We kept pulling on that thread — reorienting healthcare around the consumer while working with the existing system — first at Amazon, and then at General Medicine, which I co-founded with TJ Parker and Elliot Cohen in 2023 and have led as CEO since. A few years in and it’s working. General Medicine’s store is the only place where a customer can shop for and purchase whatever care they need, from a simple medication refill all the way to finding the right in-person specialist, nationwide, with clear, upfront pricing both with and without insurance. 83% of our customers tell us we’ve helped them address something they had been putting off. A third say it was something they had put off for six months or longer. The business has never been in a stronger position. And we’re just getting started. Earlier this year, TJ — who led our first funding rounds, serves on our board, and has been a co-founder since the beginning — told me he wanted to leave venture, get back into the weeds of operating, and do it with us at General Medicine. Bringing him on full-time was an obvious yes. Figuring out how to organize ourselves to make the most of the opportunity ahead was a harder question. I spent a lot of time thinking about where each of us could have the greatest impact and I ultimately concluded that TJ should join as CEO and that I should move into the CPO role. It’s an unconventional decision, particularly at a moment when the company is doing so well. But, that momentum is exactly why it felt like a unique moment to reorganize ourselves to maximize the opportunity ahead of us. As CPO, I’ll continue to own our consumer business and lead product, engineering, design, clinical and ops and much of the company’s day-to-day work. My focus will remain what it has been from the beginning: building a healthcare experience that puts the consumer first. One of the beautiful things about startups is that when we win, we win together. Titles, roles, and responsibilities are all downstream of organizing ourselves to have the greatest possible impact. There’s no one I’d rather build this with than Elliot, TJ and the rest of the General Medicine team, and I’ve never been more excited about what’s ahead for us. TJ, I’m sure the venture world will miss you, but we’re pretty stoked to have you back in the weeds with us. More to come from us later today.
-
Daisy Wolf reacted on thisDaisy Wolf reacted on thisI joined Amazon Pharmacy in 2019 to lead pricing because I wanted my work to really matter. I didn’t know much about pharmacy pricing, or healthcare, for that matter. But, I knew how to build marketplaces and create simple, lovable consumer experiences, even when everything under the hood was wildly complex. I also thought the newly acquired PillPack team was exceptional and that we might have some fun along the way. We kept pulling on that thread — reorienting healthcare around the consumer while working with the existing system — first at Amazon, and then at General Medicine, which I co-founded with TJ Parker and Elliot Cohen in 2023 and have led as CEO since. A few years in and it’s working. General Medicine’s store is the only place where a customer can shop for and purchase whatever care they need, from a simple medication refill all the way to finding the right in-person specialist, nationwide, with clear, upfront pricing both with and without insurance. 83% of our customers tell us we’ve helped them address something they had been putting off. A third say it was something they had put off for six months or longer. The business has never been in a stronger position. And we’re just getting started. Earlier this year, TJ — who led our first funding rounds, serves on our board, and has been a co-founder since the beginning — told me he wanted to leave venture, get back into the weeds of operating, and do it with us at General Medicine. Bringing him on full-time was an obvious yes. Figuring out how to organize ourselves to make the most of the opportunity ahead was a harder question. I spent a lot of time thinking about where each of us could have the greatest impact and I ultimately concluded that TJ should join as CEO and that I should move into the CPO role. It’s an unconventional decision, particularly at a moment when the company is doing so well. But, that momentum is exactly why it felt like a unique moment to reorganize ourselves to maximize the opportunity ahead of us. As CPO, I’ll continue to own our consumer business and lead product, engineering, design, clinical and ops and much of the company’s day-to-day work. My focus will remain what it has been from the beginning: building a healthcare experience that puts the consumer first. One of the beautiful things about startups is that when we win, we win together. Titles, roles, and responsibilities are all downstream of organizing ourselves to have the greatest possible impact. There’s no one I’d rather build this with than Elliot, TJ and the rest of the General Medicine team, and I’ve never been more excited about what’s ahead for us. TJ, I’m sure the venture world will miss you, but we’re pretty stoked to have you back in the weeds with us. More to come from us later today.
Experience
Education
Volunteer Experience
Other similar profiles
Explore more posts
-
James Hill
Thrilled to partner with Navidence and Nina Capital on this Seed round. Navidence is turning messy healthcare data into standardized, reusable definitions for clinical research. The kind of infrastructure teams can’t live without once it’s in place. Link in comments to my blog with more thoughts. Welcome to the portfolio, Aaron Kamauu MD MS MPH, Matt Veatch, and team.
4 Comments -
Stephanie Campbell
For our latest Tip of the Spear interview, we sat down with Nina Williams, Associate Director at Mount Sinai Ventures, whose career sits at the intersection of clinical operations and strategic investing. A few insights that stood out: 〜 Health systems can’t build everything. Founders need a clear answer to a simple question: Why you over an internal build? Integration into existing workflows and a solution that solves an enterprise wide pain point are critical. 〜 Co-investment reduces risk. Strategics move faster when like-minded institutions can help de-risk and validate a solution. 〜 Consumer-driven care is no longer a niche. Patients want autonomy: routing prescriptions, choosing delivery pathways, and improving healthspan (not just increasing lifespan). 〜 Founder readiness matters. Nina looks for grit, consistency, and flexibility. If a solution makes it to Investment Committee, the deal lead has to believe in the workflow just as much as the founder does, because the impact on patients and employees is very real. 〜 Finally, her best piece of career advice. Be authentic with your storytelling, and be proud of your story. Thank you, Nina, for sharing your perspective with the Artemis community! You can read the full interview at the link in the comments.
5 Comments -
Roseanne Wincek
When we first backed Epsilon Health, the company had two employees. The medical imaging industry has been hearing grand AI promises for decades. When we spoke to radiologists and imaging center operators, many of them literally used the term "snake oil." Expectations are low and the bar for implementation is extremely high. Rustin came in with a point of view we had not heard from anyone else. Epsilon sells a finished product to imaging centers that are desperate for capacity, rather than another co-pilot working its way through a health system. Epsilon is a canonical example of what we look for in an AI-native service business: a supply-constrained industry, a regulated workflow, and a job that has to get done. Rustin understands this market deeply, and he built something customers are clamoring to buy. Epsilon is now on track to review 1% of all daily U.S. X-rays in 2026. Congratulations to Rustin Rassoli, Roi Bittane MD, Arjun Karpur and the entire incredible Epsilon Health team.
1 Comment -
Christopher McKelvy
HHS just launched an AI prize competition for caregiving startups. What they’re looking for: - give caregivers on-demand support/training - help monitor well-being safely - cut admin + workflow automation Phase 1 is up to $2.5M, applications are due July 31 and they expect to give 20 awards. Caregiving is one of the biggest pressure points in America. Immigration policies have strained the workforce yet demand is growing (we have a lot of Baby Boomers). AI isn’t a silver bullet but, given the size of this market, any automation will help. If you’re building in aging, disability care, or home care, this is worth a look.
16 Comments -
Brenda Irwin
After more than two decades of investing in healthcare, I've learned three things: be patient, resist trend-chasing, and wait until timing makes sense. With experience on dozens of boards, witnessing thousands of pitches, navigating frothy portfolio activity, and surviving the dud markets while waiting on good ones to return, I know that time and timing is key for success in healthcare investing. The challenge is, how do I convince LPs that the wait will be worth it? Peek at Relentless Venture Fund diversity of companies that span regenerative medicine to software-as-a-medical-device (SaMD), includes a repeat entrepreneur who practiced medicine, to technical founders who figured out IP rights in a way that only newbies to the industry would contemplate. The beauty of diversified portfolio construction, regulatory and risk balance. Deep bets take time. That's the opportunity in healthcare investing. BC has structural advantages that make deep bets work. World-class science from The University of British Columbia, Simon Fraser University, University of Victoria, BCCA and our research hospitals. Clinical trial facilities such as the new Phase 1 Clinical Trial Unit at Providence Health Care. Provincial commitment to the innovation ecosystem such as the government's participation in Aspect Biosystems' $200M, multi-year project to ensure a world class team thrives in a world class facility in our province. What would further amplify our potential? Procurement strategies that let BC companies prove themselves locally before going global. As a member of DIGITAL's investment committee, I evaluate and advance private/public partnerships that derisk technology and accelerate commercial adoption in BC and across Canada. These collaborations are shortening the path from lab to market. Timelines for liquidity in healthcare may be longer than other venture sectors, but the wins are foreshadowed years ahead. Canary Medical Inc. locked in a commercial partnership with Zimmer Biomet before regulatory approval. Aspect secured a $2.6B partnership with Novo Nordisk on pre-clinical data. Two BC founded, Relentless portfolio companies. It will be approximately one decade from our original investment in Aspect to their first human clinical trial. I am not fussed by the timeline. Each strategic partnership and validation of data by customers sets the stage for a high value exit. The beauty of investing in healthcare innovation is regulatory timelines are getting shorter and costs are dropping; innovation is expediting discovery, diagnosis, treatment and care options never imagined when I started my VC career. I know deep science takes time, and patient capital wins. And when they do, BC has an opportunity to capture value that historically flowed south. With the right policy support and patient capital aligned, we can continue to build category defining healthcare companies that scale from our province, not just launch here and relocate. Life Sciences BC
1 Comment
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Daisy Wolf in United States
4 others named Daisy Wolf in United States are on LinkedIn
See others named Daisy Wolf